Myovant Sciences and Accord Healthcare partner to commercialise Orgovyx in Europe
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
According to the brokerage, as the pandemic has receded, the past exceptional growth in acute therapies may not be repeated (stellar double-digit growth for anti-infectives coming down)
The company is preparing the response to the observations, which will be submitted to the USFDA within 15 business days
The new framework collaboration will support due diligence into ALSA’s potential investments, which will assist with their investment de-risking
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Lupin recognized the need to digitize more applications, improve scalability, decrease risk of security breaches and eliminate critical data loss
SCG101 is an autologous T-cell receptor (TCR) T-cell therapy for liver cancer
Saumen is a postgraduate in management from IIM, Ahmedabad and an executive fellow in management from ISB, Hyderabad
Ahead of International Thalassemia Day on 8th May, medical professionals and representatives of patient bodies participated in a virtual discussion on the current situation of Thalassemia management in India
There is a need for the Ministry of Health to put it on the priority list and address the issues, which are numerous
Subscribe To Our Newsletter & Stay Updated